Acute Coronary Syndrome

AGGRASTAT injection clinical data presented at cardiology meeting

Published in Obesity and Diabetes Week, April 4th, 2005

Guilford Pharmaceuticals, Inc., (GLFD) announced the presentation of additional data from the ADVANCE trial (the additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary artery angioplasty) at the 2005 scientific sessions of the American College of Cardiology annual meeting in Orlando, Florida.

The data presented by Dr. Marco Valgimigli showed that in this study a single high-dose bolus (SHDB) regimen of AGGRASTAT Injection (tirofiban hydrochloride) improved outcomes in diabetic patients undergoing percutaneous coronary intervention (PCI) when compared to placebo.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-04-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry